Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 627.e27-627.e37

  Silveyra, María Ximena ^a,b   García Ayllón, María Salud ^a,b   Serra Basante, Carol ^a,b   Mazzoni, Valeria ^a   García Gutierrez, María Salud ^a   Manzanares, Jorge ^a   Culvenor, Janetta G ^c   Sáez Valero, Javier ^a,b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acetylcholinesterase; Acetylcholinesterase inhibitor; Alzheimer's disease; Amyloid processing; Presenilin 1; secretase

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CARBACHOL; DONEPEZIL; PRESENILIN 1; SMALL INTERFERING RNA; TACRINE;

ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME MECHANISM; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MODULATION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; UPREGULATION;

EID: 84855770450     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.04.006     Document Type: Article

References (49)

1. Basun H., Nilsberth C., Eckman C., Lannfelt L., Younkin S. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement. Geriatr. Cogn. Disord 2002, 14:156-160.
2. Bryk B., BenMoyal-Segal L., Podoly E., Livnah O., Eisenkraft A., Luria S., Cohen A., Yehezkelli Y., Hourvitz A., Soreq H. Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities. J. Neurochem 2005, 92:1216-1227.
3. Capell A., Grünberg J., Pesold B., Diehlmann A., Citron M., Nixon R., Beyreuther K., Selkoe D.J., Haass C. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J. Biol. Chem 1998, 273:3205-3211.
4. Chatel J.M., Grassi J., Frobert Y., Massoulié J., Vallette F.M. Existence of an inactive pool of acetylcholinesterase in chicken brain. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:2476-2480.
5. Chiappa S., Padilla S., Koenigsberger C., Moser V.C., Brimijoin S. Slow accumulation of acetylcholinesterase immunoreactivity in rat brain during repeated dosing with chlorpyrifos. Biochem. Pharmacol 1995, 49:955-963.
6. Clarke N.A., Soininen H., Gustafson L., Minthon L., Alhainen K., Francis P.T. Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients. Int. J. Geriatr. Psychiatry 2001, 16:1104-1106.
7. Cribbs D.H., Davis-Salinas J., Cotman C.W., Van Nostrand W.E. Aβ induces increased expression and processing of amyloid precursor protein in cortical neurons. Alzheimer Res 1995, 1:197-200.
8. Davis A.A., Fritz J.J., Wess J., Lah J.J., Levey A.I. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J. Neurosci 2010, 30:4190-4196.
9. Darreh-Shori T., Almkvist O., Guan Z.Z., Garlind A., Strandberg B., Svensson A.L., Soreq H., Hellström-Lindahl E., Nordberg A. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002, 27:563-572.
10. Darreh-Shori T., Hellström-Lindahl E., Flores-Flores C., Guan Z.Z., Soreq H., Nordberg A. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J. Neurochem 2004, 88:1102-1113.
11. Dong H., Yuede C.M., Coughlan C.A., Murphy K.M., Csernansky J.G. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain Res 2009, 1303:169-178.
12. Dori A., Cohen J., Silverman W.F., Pollack Y., Soreq H. Functional manipulations of acetylcholinesterase splice variants highlight alternative splicing contributions to murine neocortical development. Cereb. Cortex 2005, 15:419-430.
13. Duysen E.G., Stribley J.A., Fry D.L., Hinrichs S.H., Lockridge O. Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Brain Res. Dev. Brain Res 2002, 137:43-54.
14. Espallergues J., Galvan L., Lepourry L., Bonafos B., Maurice T., Chatonnet A. Hyposensitivity to the amnesic effects of scopolamine or amyloid beta(25-35) peptide in heterozygous acetylcholinesterase knockout (AChE(+/-)) mice. Chem. Biol. Interact 2008, 175:131-134.
15. Evin G., Sharples R.A., Weidemann A., Reinhard F.B., Carbone V., Culvenor J.G., Holsinger R.M., Sernee M.F., Beyreuther K., Masters C.L. Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease. Biochemistry 2001, 40:8359-8368.
16. Fu H., Li W., Luo J., Lee N.T., Li M., Tsim K.W., Pang Y., Youdim M.B., Han Y. Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity. Biochem. Biophys. Res. Commun 2008, 366:631-636.
17. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest 2005, 115:1121-1129.
18. García-Ayllón M.S., Silveyra M.X., Andreasen N., Brimijoin S., Blennow K., Sáez-Valero J. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. J. Neurochem 2007, 101:1701-1711.
19. Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scali C., Yu Q.S., Mamczarz J., Holloway H.W., Giordano T., Chen D., Furukawa K., Sambamurti K., Brossi A., Lahiri D.K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17213-17218.
20. Hu W., Gray N.W., Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J. Neurochem 2003, 86:470-478.
21. Hung A.Y., Haass C., Nitsch R.M., Qiu W.Q., Citron M., Wurtman R.J., Growdon J.H., Selkoe D.J. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J. Biol. Chem 1993, 268:22959-22962.
22. Kaether C., Haass C., Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegener. Dis 2006, 3:275-283.
23. Kaufer D., Friedman A., Seidman S., Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998, 393:373-377.
24. Lahiri D.K., Lewis S., Farlow M.R. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J. Neurosci. Res 1994, 37:777-787.
25. Lahiri D.K., Farlow M.R., Nurnberger J.I., Greig N.H. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann. N. Y. Acad. Sci 1997, 826:416-421.
26. Lahiri D.K., Chen D., Maloney B., Holloway H.W., Yu Q.S., Utsuki T., Giordano T., Sambamurti K., Greig N.H. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J. Pharmacol. Exp. Ther 2007, 320:386-396.
27. Lenzken S.C., Lanni C., Govoni S., Lucchelli A., Schettini G., Racchi M. Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem. Biol. Interact 2007, 165:138-145.
28. Li Q., Wu D., Zhang L., Zhang Y. Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells. Exp. Gerontol 2010, 45:842-847.
29. Matrone C., Ciotti M.T., Mercanti D., Marolda R., Calissano P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13139-13144.
30. Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res 2004, 145:67-78.
31. Mori F., Lai C.C., Fusi F., Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995, 6:633-636.
32. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258:304-307.
33. Pakaski M., Rakonczay Z., Kasa P. Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro. Neurochem. Int 2001, 38:219-226.
34. Peng Y., Jiang L., Lee D.Y., Schachter S.C., Ma Z., Lemere C.A. Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells. J. Neurosci. Res 2006, 84:903-911.
35. Racchi M., Sironi M., Caprera A., König G., Govoni S. Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol. Psychiatry 2001, 6:520-528.
36. Rees T.M., Berson A., Sklan E.H., Younkin L., Younkin S., Brimijoin S., Soreq H. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr. Alzheimer Res 2005, 2:291-300.
37. Rossner S., Ueberham U., Schliebs R., Perez-Polo J.R., Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol 1998, 56:541-569.
38. Rotundo R.L. Biogenesis of acetylcholinesterase molecular forms in muscle. Evidence for a rapidly turning over, catalytically inactive precursor pool. J. Biol. Chem 1988, 263:19398-19406.
39. Sáez-Valero J., Tornel P.L., Muñoz-Delgado E., Vidal C.J. Amphiphilic and hydrophilic forms of acetyl- and butyrylcholinesterase in human brain. J. Neurosci. Res 1993, 35:678-689.
40. Sberna G., Sáez-Valero J., Beyreuther K., Masters C.L., Small D.H. The amyloid β-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J. Neurochem 1997, 69:1177-1184.
41. Silveyra M.X., Evin G., Montenegro M.F., Vidal C.J., Martínez S., Culvenor J.G., Sáez-Valero J. Presenilin-1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation. Mol. Cell. Biol 2008, 28:2908-2919.
42. Sklan E.H., Lowenthal A., Korner M., Ritov Y., Landers D.M., Rankinen T., Bouchard C., Leon A.S., Rice T., Rao D.C., Wilmore J.H., Skinner J.S., Soreq H. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:5512-5517.
43. Soreq H., Seidman S. Acetylcholinesterase-new roles for an old actor. Nat. Rev. Neurosci 2001, 2:294-302.
44. St George-Hyslop P.H. Molecular genetics of Alzheimer's disease. Biol. Psychiatry 2000, 47:183-199.
45. Thinakaran G., Koo E.H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem 2008, 283:29615-29619.
46. White A.R., Maher F., Brazier M.W., Jobling M.F., Thyer J., Stewart L.R., Thompson A., Gibson R., Masters C.L., Multhaup G., Beyreuther K., Barrow C.J., Collins S.J., Cappai R. Diverse fibrillar peptides directly bind the Alzheimer's amyloid precursor protein and amyloid precursor-like protein 2 resulting in cellular accumulation. Brain Res 2003, 966:231-244.
47. Xie W., Stribley J.A., Chatonnet A., Wilder P.J., Rizzino A., McComb R.D., Taylor P., Hinrichs S.H., Lockridge O. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J. Pharmacol. Exp. Ther 2000, 293:896-902.
48. Zimmermann M., Gardoni F., Marcello E., Colciaghi F., Borroni B., Padovani A., Cattabeni F., Di Luca M. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem 2004, 90:1489-1499.
49. Zimmermann M., Borroni B., Cattabeni F., Padovani A., Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol. Dis 2005, 19:237-242.